Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
30 /100
MEDIUM RISK
Score updated Aug 28, 2026

FDMT — 4D Molecular Therapeutics, Inc. Dilution Risk Tracker

Track FDMT dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track FDMT — Get alerts when the score changes →

As of August 28, 2026, 4D Molecular Therapeutics, Inc. (FDMT) has a DilutionWatch DilutionScore of 30/100, rated MEDIUM dilution risk. 4D Molecular Therapeutics, Inc. has a market capitalization of $518.06M, 49.78M shares outstanding, 152 institutional holders tracked. Stored dilution-related fields include 45.0K outstanding warrants.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
10
📊 Float Risk
40
⚠️ Warrant Exposure
15
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for FDMT.
🔔 Track FDMT — Get forecast alerts →

Market Data

Market Cap$518.06M
Shares Outstanding49.78M
Float38.84M
Cash$361.33M
Debt$19.59M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 16.0% shares (2026Q1 vs prior)
152 institutional holders · 63.39M shares
#1 JANUS HENDERSON GROUP PLC 10.49M shares
#2 GOLDMAN SACHS GROUP INC 8.51M shares
#3 RA CAPITAL MANAGEMENT, L.P. 5.05M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest12.04M
Days to Cover17.7
% of Float31.0%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31
xbrl XBRL CONVERTIBLE 2020-12-31
Full SEC filing analysis available with free account

Recent News

No recent news

Factual FDMT Dilution Snapshot

4D Molecular Therapeutics, Inc. (FDMT) has a DilutionScore of 30/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track FDMT Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking FDMT — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for FDMT
FDMT FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.